Answers are grounded in this paper and cite their sources.
Cancer is a family of diseases caused by somatic genetic mutations. Fundamental questions remain about the causes of these mutations and their roles in shaping cellular phenotypes 1 , 2 . For example, are there generalizable mutational profiles shared across tumor types? How do mutation rates vary with sequence and cellular context? How many and which mutations in non-exomic DNA drive tumor progression and resistance to therapy? Can a patient's genomic information be used to guide treatment? High-throughput sequencing projects, such as the recent Pan-Cancer studies 3 , are discovering complex, intertwined mutagenic and selective processes.
No takes yet. Share an insight, caveat, or question.
Boutros et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: